Antibody responses to HCV vaccine antigens in infection and vaccination

感染和疫苗接种中 HCV 疫苗抗原的抗体反应

• 批准号: 9096640
• 负责人: Mansun Law
• 金额: $ 39万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-04-01 至 2021-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9096640
• 关键词: Acute; Animal Model; Antibodies; Antibody Repertoire; Antibody Response; Antigens; Antiviral Agents; Awareness; B-Lymphocytes; Biological Assay; Cause of Death; Cavia; Cell Lineage; Chronic; Clinical; Complex; Development; Disputes; Epitopes; Evaluation; Future; Genes; Genetic; Genetic Variation; Genotype; Glycoproteins; Goals; HIV; Health system; Hepatitis C; Hepatitis C Antibodies; Hepatitis C Vaccination; Hepatitis C Vaccine; Hepatitis C virus; Human; Immune; In Vitro; Individual; Infection; Knowledge; Learning; Liver Cirrhosis; Malignant neoplasm of liver; Measures; Minority; Modeling; Mus; Pan Genus; Pathway interactions; Patients; Pharmaceutical Preparations; Phase I Clinical Trials; Population; Pre-Clinical Model; Process; Public Health; Reagent; Receptors, Antigen, B-Cell; Reporting; Research; Research Project Grants; Safety; Sampling; Serum; Specificity; Structure; Symptoms; System; T-Lymphocyte Epitopes; Time; Vaccinated; Vaccination; Vaccine Antigen; Vaccine Research; Vaccines; Viral; Virus; Virus Diseases; Work; age group; base; chiron vaccine; design; human data; humanized mouse; immunogenicity; in vivo; interest; murine antibody; neutralizing antibody; nonhuman primate; novel; pre-clinical; response; tool; tool development; trend; vaccine candidate; vaccine efficacy; vaccine evaluation; vaccine trial; viral transmission

Project 1 Summary HCV infects nearly 3% of the world population and is a leading cause of liver cirrhosis and cancer. A vaccine that can stop virus transmission will be a highly valuable tool for the public health system. However, HCV is antigenically variable and an effective vaccine must target conserved immune epitopes on the virus. An important goal in HCV vaccine is to develop antigens that will elicit broadly neutralizing antibodies (bNAbs). The proposed project aims to discover the epitopes targeted by bNAbs during vaccination and natural infection, and the evolutionary pathways of bnAbs. The knowledge learned from the human studies will be applied to studying the antibody responses in mice, guinea pigs and non-human primates immunized with candidate HCV vaccine antigens. The research will help uncover the pros and cons of each animal model as a preclinical model for efficacy study of future HCV vaccine candidates. This project will contribute to the knowledge and tools for the development of a broadly effective HCV vaccine.

项目1概述